Future Horizons in PSMA-Targeted Imaging and the Management of Prostate Cancer

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

The median number of re-injections was 6 (range, 1-12).

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

In both racial cohorts, median MFS was not reached in the darolutamide group.

“Looking at our overall results, not surprisingly, we can show a clear benefit of ARPIs on overall survival," says David Fisher, MSc, MA.